PRAME antibody (AA 476-502)

Catalog No. ABIN7875177

The Rabbit Polyclonal anti-PRAME antibody is suitable to detect PRAME in samples from Human. It has been validated for WB, FACS and IHC (p).

Quick Overview for PRAME antibody (AA 476-502) (ABIN7875177)

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PRAME antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-PRAME Antibody

Binding Specificity: AA 476-502

Purpose: MAPE Antibody / PRAME

Purification: Antigen affinity

Immunogen: A portion of amino acids 476-502 from the human protein was used as the immunogen for the MAPE antibody.

Isotype: Ig Fraction

Application Details

Application Notes: The stated application concentrations are suggested starting points. Titration of the MAPE antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the MAPE antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Alternative Name: MAPE

Background: MAPE (Melanoma antigen preferentially expressed in tumors), also called PRAME (Preferentially expressed antigen of melanoma), is a protein that is preferentially expressed in tumors, particularly in melanoma. It plays a vital role in regulating cell proliferation, migration, and invasion, making it a promising target for therapeutic interventions. Studies have shown that the overexpression of MAPE protein is associated with aggressive melanoma subtypes, indicating its potential as a prognostic biomarker in melanoma patients.

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding